ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0484

Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis
Abstract Number: 0485

Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice
Abstract Number: 0486

Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis
Abstract Number: 0487

A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis
Abstract Number: 0488

Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center
Abstract Number: 0489

Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers
Abstract Number: 0490

Analysis of Emergency Department Visits by Patients with Giant Cell Arteritis: A National Population-based Study
Abstract Number: 0491

Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
Abstract Number: 0492

Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study
Abstract Number: 0493

MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center
Abstract Number: 0494

Risk for Visual Loss in Patients with Giant Cell Arteritis
Abstract Number: 0495

Seasonal Variation in the Incidence of GCA in the UK and Ireland
Abstract Number: 0496

Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker?
Abstract Number: 0497

Classification Criteria and Existing Pre-Test Probability Stratification Tools Perform Poorly in Diagnosing Giant Cell Arteritis
Abstract Number: 0498

A Longitudinal Assessment of Citrulline-specific CD4 T Cells in CCP+ at Risk Subjects and Patients with New-onset Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].